Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: Updated efficacy and safety data from a phase I trial Meeting Abstract
| Authors: | Hughes, T. P.; Cortes, J. E.; Réa, D.; Mauro, M. J.; Hochhaus, A.; Kim, D. W.; Sasaki, K.; Lang, F.; Heinrich, M. C.; Breccia, M.; Deininger, M.; Goh, Y. T.; Janssen, J. J. W. M.; Talpaz, M.; le Coutre, P.; Kapoor, S.; Cacciatore, S.; Polydoros, F.; Agrawal, N.; Mahon, F. X. |
| Abstract Title: | Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: Updated efficacy and safety data from a phase I trial |
| Meeting Title: | 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | cml; chronic myeloid leukemia; phase i; tki; asciminib; t315i |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 22 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2022 Sep 28-Oct 1 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S300 |
| Language: | English |
| ACCESSION: | WOS:000897948100267 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(22)01388-x |
| Notes: | Meeting Abstract: CML-466 -- Source: Wos |
